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Background: YKL-40, a proposed marker of inflammation and endothelial dysfunction, is associated with
atherosclerosis and an increased cardiovascular mortality in the general population. However, the relationship
between YKL-40 and arterial stiffness in hypertensive patients has not been adequately assessed.
Methods: The relationship between serum levels of YKL-40 and arterial stiffness was evaluated in 93 essential
hypertensive subjects and 80 normal subjects. Essential hypertensive subjects were divided into two groups based
upon urinary albumin-to-creatinine ratio (ACR): nonmicroalbuminuric group, (ACR <30 mg/g, n= 50) and
microalbuminuric group (ACR ≥30 mg/g, n= 43). Large artery wall stiffness was assessed by measuring femoral
arterial stiffness and carotid-femoral pulse wave velocity (cf-PWV). Serum levels of YKL-40 were determined by
enzyme-linked immunosorbent assay (ELISA).
Results: The study demonstrated that YKL-40,cf-PWV and femoral arterial stiffness were increased significantly
(P<0.05) in the hypertensive group compared with normal controls. These measurements were also increased
significantly (P<0.05) in the microalbuminuric group compared with the nonmicroalbuminuric group. YKL-40 was
positively correlated with cf-PWV(r= 0.44, P= 0.000) and femoral arterial stiffness (r= 0.42, P =0.001). Multiple linear
stepwise regression analysis showed that YKL-40 was the impact factor of arterial stiffness (P<0.05).
Conclusion: YKL-40 levels are elevated in essential hypertension subjects with an independent association between
increasing YKL-40 levels and increasing arterial stiffness. The study suggests it played a positive role of YKL-40 in the
progressing vascular complications in patients with essential hypertension.Background
Hypertension is a common cardiovascular disease. Hyper-
tension often initiates and accelerates the progression of
macrovascular events by increasing arterial wall stiffness.
YKL-40 has been suggested to be a potential biomarker of
inflammation and endothelial dysfunction. Biomarkers of
inflammation and endothelial dysfunction are associated
with cardiovascular disease. Arterial stiffening may be a
mechanism through which inflammation and (or) endo-
thelial dysfunction lead to cardiovascular disease. There-
fore, the measurement of arterial wall stiffness and serum* Correspondence: yimengd@163.com; peilibusd@hotmail.com
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reproduction in any medium, provided the orlevels of YKL-40 may be important strategies for the pre-
vention and early treatment of cardiovascular events.
Although YKL-40 has been proposed to be a new mar-
ker of inflammation, atherosclerosis and endothelial dys-
function in neoplastic, cardiovascular and metabolic
diseases, it has not been studied in the context of essen-
tial hypertension . The present study investigated the as-
sociation between the serum levels YKL-40 and large
artery compliance in subjects with essential hypertension
compared with normal subjects.Methods
Subjects
Ninety-three essential hypertensive untreated subjects in
Qilu Hospital and The Second Hospital of Shandong
University were enrolled in this study. The diagnosis was
made in accordance with the 2007 Guidelines for theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Society of Hypertension (ESH) and the European Society
of Cardiology (ESC) [1]. Blood pressures were measured
by three separate verifications. Subjects with secondary
hypertension, diabetes, chronic nephrosis, hyperlipemia,
cardiovascular diseases and/or autoimmune diseases
were excluded from the study.
The subjects with essential hypertension were divided
into two groups, based upon the urinary albumin-to-
creatinine ratio (ACR): nonmicroalbuminuric (ACR
< 30 mg/g) and microalbuminuric (ACR≥ 30 mg/g).
Normotensive subjects served as controls.
The nonmicroalbuminuric (NMA) group included 50
patients (26 females and 24 males), with a mean age of
59.2 ± 12.1 years (range 32 – 79 years). The mean systolic
blood pressure (SBP) was 157.0 ± 16.9 mmHg(range 115-
200 mmHg) and the mean diastolic blood pressure
(DBP) was 95.9 ± 10.8 mmHg(range 69-113 mmHg). The
microalbuminuric (MA) group included 43 subjects (24
female, 19 male), with a mean age of 57.9 ± 13.6 years
(range 30 – 78 years). SBP was 169.7 ± 24.3 mmHg
(range 130-240 mmHg) and DBP was 103.2 ± 20.5 mmHg
(range 70-146 mmHg).
There were 80 normotensive controls (39 females, 41
males), with a mean age of 57.7 ± 13.4 years (range 24
– 84 years). SBP was 115.9 ± 10.67 mmHg (range 90-
135 mmHg) and DBP was 76.8 ± 5.9 mmHg (range 65-
90 mmHg).
Femoral arterial systolic diameter (Ds), diastolic diam-
eter (Dd), stiffness, tensity and distensibility (calculated),
pulse wave velocity (PWV) and serum levels of YKL-40
were measured for all subjects. The clinical information
for all the subjects was collected include, fasting blood
glucose(FBG), total triglyceride(TG), total cholesterol
(TC), high density lipoprotein cholesterol (HDL), low
density lipoprotein cholesterol (LDL), blood urea nitro-
gen (BUN), serum creatinine (Cr), heart rate, height,
weight, etc. (Table 1 and Table 2) This belongs in the
results: The clinical information of the three groups have
no difference, so the three groups have comparability.
This study was approved by ethics committee of the Sec-
ond Hospital of Shandong University. All subjects pro-
vided written consent.
Ultrasound measurement
The Doppler sample volume was placed 1.5 cm superior
to the forked point of femoral artery. The femoral arter-
ial intima-media thickness (IMT), systolic diameter (Ds,
at peak of T wave on electrocardiogram), diastolic diam-
eter (Dd, at peak of R wave on electrocardiogram), the
peak systolic velocity (PSV), end diastolic velocity (EDV)
were tested at 3 different points. Femoral arterial stiff-
ness, tensity and distensibility were calculated. Stiffness =
Pulse pressure(PP)×Dd/(Ds-Dd), tensity = (Ds-Dd) × 100/Dd, distensibility = (Ds2-Dd2) × 100/(Dd2 ×PP)[2,3]. One
experienced reader who was unaware of the case control
status of the subjects performed all measurements, using a
diagnostic ultrasound system (iE33, PHILIPS Ultrasound,
Washington, US) with a L11-3 probe of 3-11 MHz.
Clinical data
Blood pressures were obtained from the right arm of
each subject using the floor stand model mercurial
sphygmomanometer (YUTU, Shanghai, China) in a sed-
ate environment after resting for 15 min. Blood pressures
were repeated twice, at two minute intervals, and the
mean value calculated. Mean pulse pressure(PPv = SBP –
DBP) was calculated for each subject. Anthropometric
measurements were obtained, and body mass index
(BMI)was calculated by the following function: BMI=
weight(kg)/height2(m2). Venous blood samples were
obtained in the morning after a 12 h fast. Tests were per-
formed by Autonomic Biochemical Analyzer (DVI1650,
BAYER, GERMANY), including FBG, TG,TC, HDL,
LDL, BUN and sCr,. The glomerular filtration rate(GFR)
was calculated: GFR(ml.min-1.1.73 m-2) = 186 × (Cr)-
1.154 × (age)-0.203 × (0.742 female).
ACR determination
An untimed urine sample was collected during visit 4.
Aliquots were frozen within 12 h and stored at -70°C. Al-
bumin and creatinine concentrations were measured in
the biochemical laboratory of Qilu Hospital, the microal-
buminuria was tested by immunoturbidimetry (assay
sensitivity, 2.0 mg/l) and the urinary creatinine by modi-
fied Benedict-Behre. The ACR was calculated automatic-
ally. ACR (mg/g) was categorized into NMA group
(ACR<30 mg/g, n= 50) and MA group (ACR ≥30 mg/g,
n= 43) [4].
Serum YKL-40 determination
The serum level of YKL-40 was determined by enzyme-
linked immunosorbent assay (ELISA, B.G,Blue Gene,
assay sensitivity, 0.01 ng/ml). . Blood samples were cen-
trifuged at 3000 rpm for 5 min after being left under
room temperature for 30 min. The supernatant was
removed, placed in Eppendorf tuber respectively and
stored at -80°C conditions for further test. Each reagent
and blood sampled was brought to room temperature for
analysis.
Cf-PWV measurement
cf-PWV measurements were assessed by an automatic
device (Complier SP, Bartech Medical, France) with the
subjects supine after resting for 15 min. The 2 press
receptors were placed at the positions of bilateral carotid
artery and femoral artery with most obvious pulse waves
Table 1 Basic characteristics X  sð Þ
essential hypertensive groups
nonmicroalbuminuric microalbuminuric healthy controls
(n=50) (n=43) (n=80)
Age 59.21 ±12.09 57.86 ± 13.63 57.69 ± 13.38
Sex distribution (M/F) 24/26 19/24 41/39
MA(mg/g) 19.92 ± 4.44* 81.44 ± 26.77*5 16.97 ± 5.84
Cr(mg/dl) 0.85 ± 0.18* 0.93 ± 0.24* 0.74 ± 1.67
GFR(ml.min-1.1.73 m-2) 89.54 ± 22.48* 88.73 ± 27.90* 113.85 ± 36.76
FPG(c/mmol.L-1) 5.79 ± 1.42 5.82 ± 1.23 5.38 ± 0.74
TC(c/mmol.L-1) 5.30 ± 1.05* 5.23 ± 0.98* 4.59 ± 0.67
HDL (c/mmol.L-1) 1.42 ± 0.38 1.33 ± 0.28* 1.50 ± 0.36
LDL(c/mmol.L-1) 2.94 ± 0.92* 3.03 ± 0.89* 2.25 ± 0.54
TG (c/mmol.L-1) 1.80 ± 1.29 2.02 ± 1.34 1.55 ± 0.72
BUN (c/mmol.L-1) 5.46 ± 1.22 5.67 ± 2.08 4.81 ± 0.86
BMI(kg/m2) 26.16 ± 2.72* 27.92 ± 3.04*5 23.68 ± 3.21
SBP(p/mmHg) 157.03 ± 16.90* 169.74 ± 24.28*5 115.94 ± 10.66
DBP(p/mmHg) 95.87 ± 10.76* 103.18 ± 20.53*5 76.81 ± 5.93
PP(p/mmHg) 59.75 ± 17.18* 66.13 ± 20.24* 39.13 ± 7.81
Data are presented as mean± SD or number. MA: microalbuminuria; Cr : serumcreatinine; GFR : the glomerular filtration rate; FPG : fasting blood glucose; TC : total
cholesterol; HDL : high density lipoprotein cholesterol; LDL : low density lipoprotein cholesterol; TG : triglyceride; BUN : blood urea nitrogen; BMI: body mass index;
SBP: systolic pressure; DBP: diastolic pressure; PP:pulse pressure;*P<0.05 vs healthy controls, 5P<0.05 vs nonmicroalbuminuric.
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PWV were recorded.
Statistical analysis
Statistical analyses were performed using SPSS 17.0 stat-
istical software package The normally distributed quanti-
tative variables were expressed as mean ± standard
deviation . Comparisons among the 3 groups were done
by ANOVA. The association of each variable withTable 2 Changes in indexes of ultrasound of femoral
artery, PWV and YKL-40 among different groups X  sð Þ
essential hypertensive groups
nonmicroalbuminuric microalbuminuric healthy controls
(n = 50) (n = 43) (n = 80)
IMT(mm) 0.87 ± 0.14* 1.08 ± 0.16*# 0.65 ± 0.14
PSV(cm/s) 96.25 ± 26.96 95.97 ± 25.28 95.34 ± 25.58
EDV(cm/s) 15.17 ± 5.12 15.46 ± 5.89 17.13 ± 6.32
stiffness 455.75 ± 199.38* 614.59 ± 234.38*# 382.14 ± 165.23
tensity 14.93 ± 7.42 12.01 ± 6.05*# 15.38 ± 7.58
distensibility 0.69 ± 0.21 0.46 ± 0.17*# 0.96 ± 0.31
cf-PWV(ms) 10.40 ±1.98* 12.26 ± 2.13*# 8.67 ± 2.90
YKL-40
(ng/ml)
61.63 ± 18.58* 98.78 ± 19.83*# 37.85 ± 14.12
Data are presented as mean± SD. IMT: intima-media thickness; PSV: peak
systolic velocity; EDV: end diastolic velocity; PWV: pulse wave velocity; *P<0.05
vs healthy controls; #P<0.05 vs nonmicroalbuminuric.femoral arterial stiffness was assessed by Pearson correl-
ation coefficients, and trend analysis was performed by
Spearman rank correlation. Application of multiple step-
wise regression analysis the affecting factors of femoral
arterial stiffness, distensibility and PWV, P<0.05 for the
difference was statistically significant.
Results
Comparison of common clinical data
There was no significant difference between the hyper-
tensive subjects and normal controls for the following
variables: age, gender, fasting blood glucose (FBG), trigly-
cerides (TG), and blood urea nitrogen (BUN). The
hypertensive patients were significantly more likely to
have an elevated creatinine (Cr), total cholesterol (TC),
low density lipoprotein cholesterol (LDL), body mass
index(BMI), systolic pressure (SBP), diastolic pressure
(DBP) and pulse pressure (PP) (P<0.05),but glomerular
filtration rate (GFR) was decreased in comparison to
normal controls. BMI, SBP and DBP were significantly
higher for subjects with MA compared to NMA subjects.
(Table 1)
The comparison of indicators arterial function
The IMT, stiffness of femoral artery, and cf-PWV were
markedly higher in hypertensive groups than in controls
which is the same in the comparison between MA group
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Figure 1 Serum level of YKL-40 in nonmicroalbuminuric and
microalbuminuric essential hypertensives. Serum level of YKL-40
was compared in nonmicroalbuminuric and microalbuminuric
essential hypertensives. The level of YKL-40 in nonmicroalbuminuric
patients is 61.63 ± 18.58, while the level of YKL-40 in
microalbuminuric group is 98.78 ± 19.83. YKL-40 was increased in
microalbuminuric patients than in nonmicroalbuminuric subjects
(P<0.05).
Figure 2 Scatter diagram of YKL-40 and cf-PWV in
normoalbuminuric and microalbuminuric hypertensions.
Spearman correlation of circulating plasma levels YKL-40 and cf-PWV.
The level of YKL positively correlate with cf-PWV in
normoalbuminuric and microalbuminuric hypertensions (r = 0.44,
P= 0.00).
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hypertensive groups than in controls (P<0.01). PSV and
EDV did not show significant difference among groups
(P> 0.05) (Table 2).The comparison of serum YKL-40
The serum YKL-40 results of each group: NMA group
(61.63 ± 18.58 ng/ml), MA group (98.78 ± 19.83 ng/ml)
and healthy controls (37.85 ± 14.12 ng/ml). YKL-40 was
significantly higher in hypertensive group than in control
group (P<0.05) and further increased in microalbuminu-
ric patients than in nonmicroalbuminuric subjects
(P<0.05) (Table 2, Figure 1).Table 3 correlation analysis between YKL-40 and the
correlated indexes (R=0.634) (n=93)









Correlation analysis between stiffness and the correlated indexes. IMT:
intima-media thickness; PWV: pulse wave velocity; MA: microalbuminuria; BMI:
body mass index.Correlation analysis between YKL-40 and the correlated
indexes
Significant positive correlations were noted between
YKL-40 and the stiffness of the femoral artery (r= 0.42,
P<0.01), cf-PWV (r= 0.44, P<0.01), MA,IMT, BMI and
age(P<0.05), while tensity and distensibility were signifi-
cantly negatively correlated to stiffness in hypertensive
group (P<0.05) (Table 3, Figure 2, Figure 3).
YKL-40 was the impact factor of arterial stiffness
With the stiffness and distensibility of the femoral ar-
tery and pulse wave velocity (PWV) as dependent
variables, age, blood pressure(SBP, DBP), BMI, bloodFigure 3 Scatter diagram of YKL-40 and stiffness(CFA) in
normoalbuminuric and microalbuminuric hypertensions.
Spearman correlation of circulating plasma levels YKL-40 and
stiffness. The level of YKL positively correlate with stiffness in
normoalbuminuric and microalbuminuric hypertensions (r= 0.42,
P= 0.001).
Table 4 Multivariate linear stepwise regression of femoral
arterial stiffness and the correlated indexes (R2 = 0.402)
(n=93)
Items partial regression standardized partial t - value P- value
coefficient β regression coefficient β
YKL-40 0.006 0.37 4.28 0.001
Age 0.011 0.36 4.26 0.000
BMI 0.031 0.23 2.72 0.008
TG -0.059 -0.17 -2.05 0.043
SBP -0.001 -0.064 -0.564 0.574
DBP 0.000 -0.022 -0.212 0.833
HDL 0.000 -0.005 -0.053 0.958
LDL 0.034 0.076 0.868 0.388
FPG -0.018 -0.046 -0.490 0.625
Multivariate linear stepwise regression of femoral arterial stiffness and the
correlated indexes (R2= 0.402)(n= 93). BMI: body mass index; TG : triglyceride;
SBP:systolic pressure; DBP: diastolic pressure; HDL: high density lipoprotein
cholesterol; LDL : low density lipoprotein cholesterol; FPG : fasting blood
glucose.
Table 6 Multivariate linear stepwise regression of the
pulse wave velocity(logPWV) and the correlated indexes
(R2 = 0.192)(n=93)
Items partial regression standardized partial t - value P- value
coefficient β regression coefficient β
YKL-40 0.009 0.401 3.735 0.000
Age 0.018 0.012 0.116 0.908
BMI 0.080 0.086 0.802 0.425
TG 0.195 0.026 0.265 0.792
SBP 0.015 0.104 0.798 0.427
DBP 0.017 -0.062 -0.509 0.612
HDL 0.014 0.054 0.514 0.609
LDL 0.259 0.038 0.378 0.706
FPG 0.234 -0.006 -0.053 0.957
Multivariate linear stepwise regression of the pulse wave velocity (PWV) and
the correlated indexes (R2=0.192)(n= 93).
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40 as independent variables by using the multivariate
linear stepwise regression analysis. The YKL-40 on
femoral artery stiffness contribution rate was 36.9%
(F = 14.781, P =0.001, Table 4). On distensibility of
contribution ratio was 36.9% (F = 10.743, P =0.000,
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您体验更加流畅Table 5 Multivariate linear stepwise regression of the
femoral arterial distensibility and the correlated indexes
(R2 = 0.193)(n=93)
Items partial regression standardized partial t - value P- value
coefficient β regression coefficient β
YKL-40 0.001 -0.385 -3.635 0.000
Age 0.002 -0.003 -0.025 0.980
BMI 0.009 0.050 0.480 0.633
TG 0.023 0.020 0.206 0.837
SBP 0.002 -0.126 -0.981 0.329
DBP 0.002 0.231 1.916 0.059
HDL 0.002 0.054 0.516 0.607
LDL 0.030 -0.015 -0.154 0.878
FPG 0.027 -0.225 -0.211 0.037
Multivariate linear stepwise regression of femoral arterial distensibility and the
correlated indexes (R2= 0.193)(n= 93).Analysis showed that YKL-40 was the impact factor ar-
terial stiffness (P<0.05).Discussion
Hypertension,a progressing in chronic inflammation and
cardiovascular syndrome with various causes, results in
functional and structural changes of heart and arterial
vessels. The evaluation of vascular damage caused by
hypertension was made in two parts: functional and
structural test, while the vascular functional abnormality
was mainly characterized as degeneration of arterial elas-
ticity. Femoral arterial stiffness, tensity and distensibility
and cf-PWV could help to observe structural changes of
vascular wall directly and evaluate vascular elasticity
objectively.
YKL-40 is a 40 kDa heparin- and chitin-binding glyco-
protein which is secreted.
Invitro by a variety of cells. InvivoYKL-40 is found in
subpopulations of macrphages and VSMCs in different
tissues with inflammation and extracellular matrix re-
modeling as in atherosclerotic plaques [5]. YKL-40 has
been suggested to be a potential biomarker of inflamma-
tion and endothelial dysfunction [5]. It is a useful screen-
ing tool because it is detected in early stage subclinical
disease, and it also appears to have the potential of be-
coming a significant prognosticator of cardiovascular
events and mortality [6] .
Our results demonstrate YKL-40 was increased signifi-
cantly in essential hypertension group and further
increased in the MA subjects compared with NMA sub-
jects. MA is a marker of target organ damage (TOD) in
hypertensive patients [7]. Decreased eGFR is associated
with an increased risk of arterial stiffness in community
residents [8]. Positive correlations were noted between
YKL-40 and MA, IMT. The common femoral artery
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descriptor [9]. It implied YKL-40 might be used as a
viewing window to observe subclinical target organ dam-
age of hypertension. Serum level of YKL-40 was signifi-
cantly associated with femoral stiffness, tensity and
distensibility. YKL-40 was an independent predicator of
functional changes of artery, implicating that high level
of YKL-40 affects arterial compliance. To the best of our
knowledge, we detected there is a strong relationship be-
tween increased serum level of YKL-40 and essential
hypertension for the first time. Hypertension is intimate
correlated with inflammation. YKL-40 is a marker of in-
flammation and endothelial dysfunction [10].
Femoral arterial stiffness could access arterial elasticity
directly. Many factors take part in elevation of arterial
stiffness. The participation of YKL-40 in inflammatory
states and vascular processes implies that YKL-40 may
play a role in endothelial dysfunction and atherosclerosis.
YKL-40 is an inflammatory glycoprotein involved in
endothelial dysfunction by promoting chemotaxis, cell
attachment and migration, reorganization and tissue re-
modelling as a response to endothelial damage [11]. We
found microalbuminuric patients’ YKL-40 and stiffness
increased and tensity and distensibility decreased were
comparable with nonmicroalbuminuric patients. YKL-40
was positively correlated with femoral arterial stiffness
and it was the impact factor of stiffness of femoral artery.
Subendothelial abnormal deposit and deformation of
lipid resulted from inflammatory response and oxidative
stress,resulted in endothelial proliferation,followed by
fibrillation and elevation in endothelial thickness. All-
layer-involved diffuse and continuous increase in arterial
stiffness, vascular dilation and elevation in endothelial
thickness provided basis for formation of artherosclero-
sis. cf-PWV is a common method to evaluate the func-
tion of vessels and a classic index to evaluate the
stiffness of artery [12]. Mori J Krantz et al. [13] reported
that PWV was associated with preclinical carotid athero-
sclerosis independent of Framingham risk factors in
cross-sectional study of a mixed-ethnicity population.
PWV is associated with preclinical atherosclerosis among
a Latino-predominant population. PWV as an indicator
of arterial distensibility, may play an important role in
the stratification of patients based on the cardiovascular
risk. PWV inversely correlates with arterial distensibility
and relative arterial compliance. In our study, microalbu-
minuric group had higher levels of cf-PWV compared
with those of nonmicroalbuminuric group. The MA sub-
jects also had significantly lower arterial tensity and dis-
tensibility compared with controls. YKL-40 was
positively correlated with cf-PWV, demonstrating a rela-
tionship probably existed betweenYKL-40 and cf-PWV.
Multiple linear regression analysis confirmed YKL-40
was femoral artery stiffness and cf-PWV independentfactors. It can be used a valuable index to evaluated ar-
terial function and further predict complication in essen-
tial hypertension.
YKL-40, MA, cf-PWV and the femoral arterial stiffness
increase progressively with an increase in SBP and DBP.
Recent work has identified YKL-40 as a promoter of
angiogenesis in neoplasms, including activating the mito-
gen activated protein kinase/extracellular signal regu-
lated kinase (MAPK/ERK) pathway in endothelial cells
[14]. Activated MAPK and/or Akt may be negatively
regulated by EGFR. Both pathways are required for the
cells to complete mitosis and the activation of these
pathways stimulates the growth of connective tissue cells
[15]. Next we will investigate the interaction between
MAPK signaling and YKL-40 in essential hypertension.
Conclusions
In summary, the present investigation demonstrated that
a positive correlation exists between YKL-40 and femoral
arterial stiffness and cf-PWV. YKL-40 was the impact
factor of arterial wall stiffness, the mechanism possibly
related to arterial endothelium dysfunction. YKL-40 is
sensitive indicators that could predict early target organ
damage and evaluate arterial function in hypertension.
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